SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, ...

Data from a nationwide German registry with data from nearly 3,000 long-term survivors of radical prostatectomy sheds light on how frailty impacts the lives they lead. Treat or observe? Dr. Joseph ...

The 2024 NCCN Guidelines for Prostate Cancer have been updated four times to-date, integrating new FDA-approved drugs for the treatment of prostate cancer as well as new scientific data that could ...

In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...

Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...

BOSTON, Nov. 21, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first direct-to-patient, personalized, and evidence-based cancer navigation platform, and the National Comprehensive Cancer ...